TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Treatment Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Necrotising Enterocolitis (NEC) Market, by Stages
6.1 Introduction
6.2 Stage I
6.2.1 Market Estimates & Forecast, 2023–2030
6.3 Stage II
6.3.1 Stage IIa
6.3.2 Stage IIb
6.4 Stage III
6.4.1 Stage IIa
6.4.2 Stage IIb
Chapter 7. Global Necrotising Enterocolitis (NEC) Market, by Diagnosis
7.1 Introduction
7.2 Imaging
7.2.1 Abdominal X-Ray
7.2.2 Magnetic Resonance Imaging (MRI)
7.2.3 Ultrasound
7.2.4 Laparoscopy
7.2.5 Angiography
7.2.6 Others
7.3 Laboratory Studies
7.3.1 Haemochromocytometric Exam
7.3.2 Blood Culture
7.3.3 Serum Electrolytes
7.3.4 Arterial Blood Gas Analysis
7.3.5 Blood Pressure Monitor
7.4 Differential Diagnosis
7.4.1 Ileus Secondary to Neonatal Sepsis
7.4.2 Spontaneous Intestinal Perforation
7.4.3 Ileal Atresia
7.4.4 Intestinal Malrotation
7.4.5 Volvulus
7.4.6 Neonatal Appendicitis
7.4.7 Neonatal Pseudomembranous Colitis
7.4.8 Others
Chapter 8. Global Necrotising Enterocolitis (NEC) Market, by Treatment
8.1 Introduction
8.2 Total Parenteral Nutrition (TPN),
8.2.1 Market Estimates & Forecast, 2023–2030
8.3 Gastrointestinal Decompression
8.3.1 Market Estimates & Forecast, 2023–2030
8.4 Antimicrobial Therapy
8.4.1 Market Estimates & Forecast, 2023–2030
8.5 Antifungal Treatment
8.5.1 Market Estimates & Forecast, 2023–2030
8.6 Paracentesis
8.6.1 Market Estimates & Forecast, 2023–2030
8.7 Others
Chapter 9. Global Necrotising Enterocolitis (NEC) Market, by End-User
9.1 Introduction
9.2 Hospitals & Clinics
9.2.1 Market Estimates & Forecast, 2023–2030
9.3 Ambulatory Surgical Center
9.3.1 Market Estimates & Forecast, 2023–2030
9.4 Diagnostic Centers
9.4.1 Market Estimates & Forecast, 2023–2030
9.5 Others
9.5.1 Market Estimates & Forecast, 2023–2030
Chapter. 10 Global Necrotising Enterocolitis (NEC) Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 U.K.
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Rest of the Middle East & Africa
Chapter 11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
Chapter 12 Company Profiles
12.1 GlaxoSmithKline plc
12.1.1 Company Overview
12.1.2 Stages Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Company Overview
12.2.2 Stages Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Pfizer Inc.
12.3.1 Company Overview
12.3.2 Stages Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Eli Lilly and Company
12.4.1 Company Overview
12.4.2 Stages/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Bayer HealthCare AG
12.5.1 Company Overview
12.5.2 Stages Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Becton, Dickinson and Company
12.6.1 Company Overview
12.6.2 Stages Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 Bristol-Myers Squibb Company
12.7.1 Overview
12.7.2 Stages Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Medtronic Plc
12.8.1 Company Overview
12.8.2 Stages/Business Segment Overview
12.8.3 Financial Overview
12.8.4 Key Development
12.8.5 SWOT Analysis
12.9 Others
Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of the Pharmaceutical industry
Chapter 14 Appendix
LIST OF TABLES
Table 1 Necrotising Enterocolitis (NEC) Industry Synopsis, 2023–2030
Table 2 Necrotising Enterocolitis (NEC) Market Estimates and Forecast, 2023–2030, (USD Million)
Table 3 Necrotising Enterocolitis (NEC) Market, by Region, 2023–2030, (USD Million)
Table 4 Necrotising Enterocolitis (NEC) Market, by Stages, 2023–2030, (USD Million)
Table 5 Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2023–2030, (USD Million)
Table 6 Necrotising Enterocolitis (NEC) Market, by Treatment, 2023–2030, (USD Million)
Table 7 Necrotising Enterocolitis (NEC) Market, by End-User, 2023–2030, (USD Million)
Table 8 North America Necrotising Enterocolitis (NEC) Market, by Stages, 2023–2030, (USD Million)
Table 9 North America Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2023–2030, (USD Million)
Table 10 North America Necrotising Enterocolitis (NEC) Market, by Treatment, 2023–2030, (USD Million)
Table 11 North America Necrotising Enterocolitis (NEC) Market, by End-User, 2023–2030, (USD Million)
Table 12 U.S. Necrotising Enterocolitis (NEC) Market, by Stages, 2023–2030, (USD Million)
Table 13 U.S. Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2023–2030, (USD Million)
Table 14 U.S. Necrotising Enterocolitis (NEC) Market, by Treatment, 2023–2030, (USD Million)
Table 15 U.S. Necrotising Enterocolitis (NEC) Market, by End-User, 2023–2030, (USD Million)
Table 16 Canada Necrotising Enterocolitis (NEC) Market, by Stages, 2023–2030, (USD Million)
Table 17 Canada Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2023–2030, (USD Million)
Table 18 Canada Necrotising Enterocolitis (NEC) Market, by Treatment, 2023–2030, (USD Million)
Table 19 Canada Necrotising Enterocolitis (NEC) Market, by End-User, 2023–2030, (USD Million)
Table 20 South America Necrotising Enterocolitis (NEC) Market, by Stages, 2023–2030, (USD Million)
Table 21 South America Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2023–2030, (USD Million)
Table 22 South America Necrotising Enterocolitis (NEC) Market, by Treatment, 2023–2030, (USD Million)
Table 23 South America Necrotising Enterocolitis (NEC) Market, by End-User, 2023–2030, (USD Million)
Table 24 Europe Necrotising Enterocolitis (NEC) Market, by Stages, 2023–2030, (USD Million)
Table 25 Europe Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2023–2030, (USD Million)
Table 26 Europe Necrotising Enterocolitis (NEC) Market, by Treatment, 2023–2030, (USD Million)
Table 27 Europe Necrotising Enterocolitis (NEC) Market, by End-User, 2023–2030, (USD Million)
Table 28 Western Europe Necrotising Enterocolitis (NEC) Market, by Stages, 2023–2030, (USD Million)
Table 29 Western Europe Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2023–2030, (USD Million)
Table 30 Western Europe Necrotising Enterocolitis (NEC) Market, by Treatment, 2023–2030, (USD Million)
Table 31 Western Europe Necrotising Enterocolitis (NEC) Market, by End-User, 2023–2030, (USD Million)
Table 32 Eastern Europe Necrotising Enterocolitis (NEC) Market, by Stages, 2023–2030, (USD Million)
Table 33 Eastern Europe Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2023–2030, (USD Million)
Table 34 Eastern Europe Necrotising Enterocolitis (NEC) Market, by Treatment, 2023–2030, (USD Million)
Table 35 Eastern Europe Necrotising Enterocolitis (NEC) Market, by End-User, 2023–2030, (USD Million)
Table 36 Asia Pacific Necrotising Enterocolitis (NEC) Market, by Stages, 2023–2030, (USD Million)
Table 37 Asia Pacific Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2023–2030, (USD Million)
Table 38 Asia Pacific Necrotising Enterocolitis (NEC) Market, by Treatment, 2023–2030, (USD Million)
Table 39 Asia Pacific Necrotising Enterocolitis (NEC) Market, by End-User, 2023–2030, (USD Million)
Table 40 The Middle East & Africa Necrotising Enterocolitis (NEC) Market, by Stages, 2023–2030, (USD Million)
Table 41 The Middle East & Africa Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2023–2030, (USD Million)
Table 42 The Middle East & Africa Necrotising Enterocolitis (NEC) Market, by Treatment, 2023–2030, (USD Million)
Table 43 The Middle East & Africa Necrotising Enterocolitis (NEC) Market, by End-User, 2023–2030, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Necrotising Enterocolitis (NEC) Market
Figure 3 Segmentation Market Dynamics for Necrotising Enterocolitis (NEC) Market
Figure 4 Global Necrotising Enterocolitis (NEC) Market Share, by Stages 2023
Figure 5 Global Necrotising Enterocolitis (NEC) Market Share, by Diagnosis 2023
Figure 6 Global Necrotising Enterocolitis (NEC) Market Share, by Treatment, 2023
Figure 7 Global Necrotising Enterocolitis (NEC) Market Share, by End-User, 2023
Figure 9 Global Necrotising Enterocolitis (NEC) Market Share, by Region, 2023
Figure 10 North America Necrotising Enterocolitis (NEC) Market Share, by Country, 2023
Figure 11 Europe Necrotising Enterocolitis (NEC) Market Share, by Country, 2023
Figure 12 Asia Pacific Necrotising Enterocolitis (NEC) Market Share, by Country, 2023
Figure 13 The Middle East & Africa Necrotising Enterocolitis (NEC) Market Share, by Country, 2023
Figure 14 Global Necrotising Enterocolitis (NEC) Market: Company Share Analysis, 2023 (%)
Figure 15 GlaxoSmithKline plc: Key Financials
Figure 16 GlaxoSmithKline plc: Segmental Revenue
Figure 17 GlaxoSmithKline plc: Geographical Revenue
Figure 18 F. Hoffmann-La Roche Ltd: Key Financials
Figure 19 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 20 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 21 Pfizer Inc.: Key Financials
Figure 22 Pfizer Inc.: Segmental Revenue
Figure 23 Pfizer Inc.: Geographical Revenue
Figure 24 Eli Lilly and Company: Key Financials
Figure 25 Eli Lilly and Company: Segmental Revenue
Figure 26 Eli Lilly and Company: Geographical Revenue
Figure 27 Bayer HealthCare AG.: Key Financials
Figure 28 Bayer HealthCare AG.: Segmental Revenue
Figure 29 Bayer HealthCare AG.: Geographical Revenue
Figure 30 Becton, Dickinson and Company: Key Financials
Figure 31 Becton, Dickinson and Company: Segmental Revenue
Figure 32 Becton, Dickinson and Company: Geographical Revenue
Figure 33 Bristol-Myers Squibb Company: Key Financials
Figure 34 Bristol-Myers Squibb Company: Segmental Revenue
Figure 35 Bristol-Myers Squibb Company: Geographical Revenue
Figure 36 Medtronic Plc: Key Financials
Figure 37 Medtronic Plc: Segmental Revenue
Figure 39 Medtronic Plc: Geographical Revenue
